Printer Friendly

GULL LABS RECEIVES FDA CLEARANCE FOR RESPIRATORY INFECTION TESTS

 GULL LABS RECEIVES FDA CLEARANCE FOR RESPIRATORY INFECTION TESTS
 SALT LAKE CITY, March 11 /PRNewswire/ -- Gull Laboratories, Inc. (NASDAQ: GULL), a Salt Lake City-based manufacturer of diagnostic test kits, has obtained FDA clearances to market four kits in its new line of tests for respiratory infections. Now available for routine hospital and clinical laboratory use are direct fluorescence tests for influenza type A, influenza type B, respiratory syncytial virus (RSV) and an indirect fluorescence test for cytomegalovirus early antigen (CMV-EA).
 The new product line is designed to speed the diagnosis of respiratory infections by shortening the time required to isolate virus in cell culture. The direct fluorescent tests can provide diagnostic information within 18 hours of specimen collection, compared to as long as several days by conventional cell culture methods. "More than 90 percent of acute respiratory infections in adults are caused by viruses," said Myron Wentz, Ph.D., president of Gull Laboratories. "As vaccines and drug therapies are being developed for viral infections, accurate diagnosis of which infectious agent is causing the illness is becoming more important." Additional tests for parainfluenza, types 1, 2 and 3, and adenovirus are now being prepared for FDA review.
 Founded in 1974, Gull Laboratories, Inc., develops, manufactures and makes high quality diagnostic test kits for the detection of infectious diseases. From corporate headquarters in Salt Lake City, the company markets its products for use in hospitals and clinical laboratories in 35 countries around the world.
 -0- 3/11/92
 /CONTACT: Peter Van Duser of Gull Laboratories, 801-263-3524, or John Metzger of Metzger Associates, 303-786-7000, for Gull Laboratories/
 (GULL) CO: Gull Laboratories Inc. ST: Utah IN: MTC SU:


SH-TQ -- NY013 -- 7252 03/11/92 10:30 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 11, 1992
Words:283
Previous Article:ROADMASTER FORECASTS RECORD 1992 REVENUES COMPANY AND DP END MERGER NEGOTIATIONS
Next Article:SPRINT INTRODUCES PRODUCTIVITY PLUS VOICE PROCESSING SYSTEM
Topics:


Related Articles
GULL LABS' CHAGAS' TEST RECEIVES FDA CLEARANCE
ALAMAR BIOSCIENCES RECEIVES LAST PENDING FDA CLEARANCE; FULL PRODUCT LINE NOW AVAILABLE WORLDWIDE
MERIDIAN RELEASES FOURTH IMMUNOCARD PRODUCT
GULF LABORATORIES GAINS FDA CLEARANCE FOR RUBELLA TEST
GULL LABORATORIES LAUNCHES EPSTEIN-BARR VIRUS TEST
GULL LABORATORIES GAINS FDA CLEARANCE FOR EBV TEST
Gull Labs Receives FDA Clearance for Toxo IgG Test
Gull Labs Receives FDA Clearance for Mumps IgG Test
Gull Labs Reports 1st Quarter 1998 Results

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters